Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection

Full text
Saia, Rafael Simone [1] ; Giusti, Humberto [1] ; Luis-Silva, Fabio [2, 3] ; Bonicenha Pedroso, Karina de Jesus [4] ; Auxiliadora-Martins, Maria [2] ; Loro Morejon, Karen Mirna [4] ; Degiovani, Augusto Marcussi [5] ; Cadelca, Marcia Regina [6] ; Basile-Filho, Anibal [2]
Total Authors: 9
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Physiol, Lab Intestinal Pathophysiol, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Div Intens Care Med, Ribeirao Preto, SP - Brazil
[3] Fundacao Hosp Santa Lydia, Intens Care Unit, Ribeirao Preto, SP - Brazil
[4] Hosp Unimed Ribeirao Preto, Ribeirao Preto, SP - Brazil
[5] Santa Casa Misericordia, Intens Care Unit, Ribeirao Preto, SP - Brazil
[6] Hosp & Maternidade Santa Isabel, Intens Care Unit, Jaboticabal, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Web of Science Citations: 0

Objectives: SARS-CoV-2 exhibits tropism for the gastrointestinal tract; however, lesions in enterocytes and their correlation with disease severity and patient prognosis are still unknown. Methods: SARS-CoV-2 patients were enrolled in 5 medical centres in Sao Paulo, Brazil and their clinical characteristics and laboratory findings recorded. At admission, day 7 and day 14 of hospitalisation, plasma and urine samples were collected, and cytokine levels and intestinal fatty acid-binding protein (I-FABP) concentrations measured. Results: COVID-19 patients displayed approximate to 48-, 74-and 125-fold increased urinary I-FABP levels at admis-sion ( n = 283; P < 0.001), day 7 ( n = 142; P < 0.01) and day 14 ( n = 75; P < 0.01) of hospitalisation. Critically ill patients and nonsurvivors showed higher I-FABP concentrations compared with patients with less severe illness. At admission, infected patients demonstrated enhanced production of plasma interferon (IFN)-gamma and interleukin (IL)-6. The receiver operating characteristic curve suggested I-FABP as a biomarker for COVID-19 disease severity at admission ( P < 0.0 0 01; Youden index = 6.89; area under the curve = 0.699). Patients with I-FABP >= 6.89 showed higher IL-6 and C-reactive protein levels ( P < 0.001) at admission and had a prolonged length of hospital stay. Conclusions: Our findings revealed damage to enterocytes in SARS-CoV-2 infection, which is associated with illness severity, poor prognosis and exacerbated inflammatory response. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. (AU)

FAPESP's process: 20/10097-5 - Assessment of the integrity of the intestinal epithelial barrier in patients infected with SARS-COVID-2: a multicenter study
Grantee:Rafael Simone Saia
Support type: Regular Research Grants